ARTA
NVET

A.R.T. Advisors’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

A.R.T. Advisors’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-13,020
Closed -$44K – 1850
2015
Q4 		$44K Buy
+13,020
New +$51.4K ﹤0.01% 1387

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

A.R.T. Advisors's NVET Position: Q1 2016 in Review

A.R.T. Advisors sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q1 2016, closing a stake of 13,020 shares — an estimated $44K sold.

A.R.T. Advisors first reported a position in NVET in Q4 2015 and held it in 1 quarter. The position peaked at $44K in Q4 2015. 18 funds tracked by Wall St. Rank hold NVET as of Q1 2016.

  • A.R.T. Advisors reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q1 2016 after selling out during the quarter.
  • A.R.T. Advisors sold 13,020 Nexvet Biopharma plc Ordinary Shares shares in Q1 2016, an estimated $44K.
  • A.R.T. Advisors first reported a position in Nexvet Biopharma plc Ordinary Shares in Q4 2015 and held it in 1 quarter.
  • A.R.T. Advisors's Nexvet Biopharma plc Ordinary Shares position peaked at $44K in Q4 2015.
  • 18 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q1 2016.

Based on A.R.T. Advisors's 13F filing for Q1 2016, filed 16 May 2016.